GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that…
The protein RasGRP1 is a key culprit for involuntary movements that arise from dopamine replacement therapies used to treat Parkinson’s disease, a new study done in animals suggests. Targeting this protein may be a therapeutic strategy to prevent these motor problems, while still receiving the benefits of treatment. The…
Certain features of metabolic syndrome may be more prevalent in people with Parkinson’s disease-associated mutations in the gene LRRK2, new research suggests. The research abstract “Metabolic syndrome and genetic Parkinson’s disease, the case of LRRK2 and GBA” was published online. It was to be presented at the 2020 annual meeting…
To help patients and their families cope with the global COVID-19 outbreak, The Michael J. Fox Foundation (MJFF) is launching a limited-series podcast. The series begins today, May 6, and is part of MJFF’s ongoing Parkinson’s Podcast. It’s available every other Wednesday on michaeljfox.org/podcasts, Google…
An estimated one million Americans have Parkinson’s disease. Nobody knows how many of them also are infected with COVID-19, but the experts do offer sound advice about how Parkinson’s patients can avoid getting sick in the first place. Rachel Dolhun, MD, is vice-president of medical communications at the New York-based…
Scientists have developed a new light-based deep brain stimulation method that when applied to neurons located in the subthalamic nucleus (STN) — a brain region involved in controlling movement — alleviated motor symptoms in a rat model of Parkinson’s disease. The study detailing that research, “…
Researchers have developed short gene promoters — structures that act like switches to turn on genes — that may boost the effectiveness of gene therapies targeting the central nervous system. These promoters allow for the delivery of larger genes into the central nervous system while keeping them active for…
The United States Food and Drug Administration (FDA) has granted breakthrough device designation to PhotoPharmics‘s light-based, at-home device as an add-on therapy for Parkinson’s disease. This designation is given to medical devices with the potential to offer more effective treatment for life-threatening or debilitating diseases. It grants…
Comparing the genomes of people with Parkinson’s disease to the specific genes expressed by cell types in the nervous system revealed an unexpected association between Parkinson’s and the digestive nervous system, according to a study. Another surprising result linked Parkinson’s to cells called oligodendrocytes, nervous system cells that…
Special bioelectronic devices that can be placed inside a person to diagnose, monitor, and treat neurological disorders, including Parkinson’s disease and epilepsy, may have taken a major step forward with the design of soft and flexible devices that are also biocompatible. Dion Khodagholy, PhD, assistant professor of…
Get regular updates to your inbox.
